Stock Details
GRFS is Grifols, S.A.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 12.12$. Average daily volumn in 3 months 866.92k. Market cap 11.39B

Stock symbol : GRFS. Exchange : NasdaqGS. Currency : USD
Lastest price : 12.49$. Total volume : 930.55k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Grifols, S.A. (GRFS)
Last Price

Previous Close11.88
Day Range11.74-12.50
Bid10.00 x 1.8k
Ask13.50 x 1.4k
Average Volume866.92k
Market Cap11.39B
52 Week Range10.10-17.24
Trailing P/E40.29
Foward P/E14.52
Dividend (Yield %)N/A
Ex-Dividend Date2021-06-03

Financial Details

According to Grifols, S.A.'s financial reports the company's revenue in 2021 were 4.93B an decrease(-20%) over the years 2020 revenue that were of 5.34B. In 2021 the company's total earnings were 182.8M while total earnings in 2020 were 618.55M(-70.55%).

Loading ...


Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting fa... ctors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Market Cap:
Total Assets:
Total Cash:

News about "Grifols, S.A."


Grifols, S.A. (NASDAQ:GRFS) Receives Consensus Recommendation of “Hold” from Brokerages

Source from : Defense World - 12 days ago

Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) have earned an average recommendation of “Hold” from the eight ratings firms that are presently covering the company, Marketbeat reports. One ...See details»


Grifols (NASDAQ:GRFS) Stock Price Down 8.2% on Analyst Downgrade

Source from : Defense World - 5 days ago

Grifols, S.A. (NASDAQ:GRFS – Get Rating) was down 8.2% on Wednesday after Berenberg Bank lowered their price target on the stock from €21.40 to €20.60. Berenberg Bank currently has a buy rating on the ...See details»

Kepler Capital Sticks to Its Hold Rating for Grifols SA (GRFS)

Source from : The Globe and Mail - 2 days ago

Kepler Capital analyst Dariusz Ubik maintained a Hold rating on Grifols SA (GRFS – Research Report) on July 1 and set a price target of EUR22.90. The companys shares closed last Friday at $12.49.See details»

Grifols S.A. (GRFS) is on the roll with an average volume of 955.04K in the recent 3 months

Source from : investchronicle - 4 days ago

Grifols S.A. (GRFS) is priced at $11.30 after the most recent trading session. At the very opening of the session, the stock price was $11.41 and reached a high price of $11.45, prior to closing the ...See details»

Grifols, S.A. (NASDAQ:GRFS) Receives Average Rating of “Hold” from Brokerages

Source from : ETF Daily News - 12 days ago

Shares of Grifols, S.A. (NASDAQ:GRFS – Get Rating) have been assigned a consensus rating of “Hold” from the eight research firms that are covering the stock, reports.See details»


Grifols tells investors is not currently studying capital hike - source

Source from : Reuters - 5 days ago

Spanish pharmaceuticals company Grifols is not analysing any increase in share capital for the timebeing, Grifols' vice president told investors on Thursday, according to a market source.See details»

Pharma giant gets rolling on 300-job Clayton expansion that could get even bigger

Source from : The Business Journals - 7 days ago

Back in June 2020, Grifols S.A. (Nasdaq: GRFS) announced it was expanding in Clayton by adding 300 jobs through a $350 million investment. Earlier this month, the Clayton Town Council approved a ...See details»

Grifols SA Pref (GRLSbn)

Source from : - 7 days ago

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...See details»

Interesting GRFS Put And Call Options For February 2023

Source from : Nasdaq - 13 days ago

Investors in Grifols SA, Barcelona (Symbol: GRFS) saw new options become available this week, for the February 2023 expiration. One of the key inputs that goes into the price an option buyer is ...See details»

GRFS Crosses Above Key Moving Average Level

Source from : Nasdaq - 7 days ago

In trading on Monday, shares of Grifols SA, Barcelona (Symbol: GRFS) crossed above their 200 day moving average of $12.14, changing hands as high as $12.30 per share. Grifols SA, Barcelona shares ...See details»


Grifols destina 18,9 millones a transferencias de valor en Europa, un 41% más

Source from : Capitalbolsa - 1 days ago

Grifols ha aumentado las transferencias de valor en Europa en 2021 hasta los 18,9 millones de euros, un 41% más que en 2020, según ha informado la compañía radicada en Barcelona.See details»

Plasma Fractionation Market Share Growing Rapidly with Leading Players 2028 | Grifols, S.A., Octapharma AG, Kedrion S.P.A., Shire plc

Source from : Digital Journal - 7 days ago

The global plasma fractionation market size was significantly robust in 2020 and is expected to register a steady revenue CAGR over the forecast period. Key factors providing impetus to market ...See details»

US Intravenous Immunoglobulin Market See Incredible Growth 2022-2028 | Biotest AG, Octapharma AG, Grifols S.A., Kedrion Biopharma

Source from : Digital Journal - 12 days ago

U.S. Intravenous Immunoglobulin Market: An in-depth study of statistics on current and emerging trends sheds light on the dynamics of the U.S. Intravenous Immunoglobulin Market. To understand a ...See details»

Grifols: Aspectos a destacar del Investor´s Day.

Source from : Capitalbolsa - 4 days ago

El Investor´s Day de Grifols nos ha servido principalmente para confirmar que, la recuperación del negocio subyacente prosigue su marcha ascendente, incluso acelerándose en las últimas semanas en para ...See details»